KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Q3 2025 value amounting to -$2.1 billion.

  • Acadia Pharmaceuticals' Retained Earnings rose 1112.26% to -$2.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.1 billion, marking a year-over-year increase of 1112.26%. This contributed to the annual value of -$2.2 billion for FY2024, which is 931.58% up from last year.
  • Latest data reveals that Acadia Pharmaceuticals reported Retained Earnings of -$2.1 billion as of Q3 2025, which was up 1112.26% from -$2.2 billion recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Retained Earnings peaked at -$2.1 billion during Q1 2021, and registered a low of -$2.5 billion during Q3 2023.
  • Moreover, its 5-year median value for Retained Earnings was -$2.3 billion (2022), whereas its average is -$2.3 billion.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Retained Earnings crashed by 1450.83% in 2021 and then soared by 1112.26% in 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Retained Earnings (Quarter) stood at -$2.2 billion in 2021, then fell by 10.03% to -$2.4 billion in 2022, then decreased by 2.59% to -$2.4 billion in 2023, then rose by 9.32% to -$2.2 billion in 2024, then rose by 5.33% to -$2.1 billion in 2025.
  • Its last three reported values are -$2.1 billion in Q3 2025, -$2.2 billion for Q2 2025, and -$2.2 billion during Q1 2025.